Stockscreener 앱 받기
25.40
1.74%
-0.45
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses - Sahm
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB - MarketBeat
NewAmsterdam Pharma Warrant (NAMSW) Flat at $16.72 as Range-Bound Trading PersistsVolume Breadth - vinanet.vn
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $16.72 as Trading Range TightensAAII Neutral - vinanet.vn
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan
NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer - Stock Titan
Newamsterdam Pharma Company N.V. Announces Executive Changes - marketscreener.com
NewAmsterdam Pharma (NAMS) Slips 0.30% to $26.59, Holds Within Established RangeIV Rank - Vinanet
NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain - Sahm
NewAmsterdam Pharma (NAMS) Edges Higher to $27.83 as Range-Bound Trading PersistsBreakout Stock Alerts - vinanet.vn
Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative? - webull.com
How Newamsterdam Pharma Company N.v. (NAMS) Affects Rotational Strategy Timing - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring an 83.24% Potential Upside in Biotech - DirectorsTalk Interviews
HC Wainwright Issues Pessimistic Outlook for NAMS Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2027 Earnings - MarketBeat
NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires - Bitget
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
(NAMSW) Volatility Zones as Tactical Triggers - Stock Traders Daily
FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake - Stock Titan
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - The Manila Times
NewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingView
NewAmsterdam Pharma Co N.V. Q2 2026: Revenue $3.7M, EPS $(0.52) — 10-Q Summary - TradingView
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - 富途牛牛
NAMS Q2'26 Earnings: revenue estimate is 1.88M USD - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring An 86.77% Upside Potential - DirectorsTalk Interviews
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $17.19 as Traders Eye Key Support and Resistance LevelsMAMA Signal - Vinanet
NewAmsterdam Pharma Q1 2026 Earnings: EPS Beat Narrower Than Expected, Stock Edges DownBuyback Announcement Report - dars.gov.et
(NAMS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP - MarketBeat
NewAmsterdam Pharma to Host Investor Day on August 5, 2026 - GlobeNewswire
NewAmsterdam Pharma Warrants (NAMSW) Decline 6.58% as Selling Pressure MountsVWAP Breakout - dars.gov.et
Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NAMS|NewAmsterdam Pharma Company NV|Price:30.190|Chg%:+0.550 - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Income Statement - TradingKey
TradingKey - TradingKey
NewAmsterdam Pharma says EU CHMP backs approval of Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Cash Flow - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha
NAMS|NewAmsterdam Pharma Company NV|Price:29.640|Chg%:-0.910 - TradingKey
NewAmsterdam says EU CHMP backs Ubeslo, Evlarco cholesterol drugs for approval - Bitget
NewAmsterdam Pharma (NAMS) Slides 2.98% as Biotech Sector Faces HeadwindsNews Sentiment - dars.gov.et
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
NewAmsterdam Pharma Company N.V. Revenue Breakdown – NASDAQ:NAMS - TradingView
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
0.86%
0.31%
자본화:
|
볼륨(24시간):